Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

Autor: Wierda, W. G., Allan, J. N., Siddiqi, T., Kipps, T. J., Opat, S., Tedeschi, Alessandra, Badoux, X. C., Kuss, B. J., Jackson, S., Moreno, Carol, Jacobs, R. M. D., Pagel, J. M., Flinn, I., Pak, Y., Zhou, Cathy, Szafer-Glusman, E., Ninomoto, J., Dean, James P, James, D. F., Ghia, Paolo, Tam, C. S., Universitat Autònoma de Barcelona

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 34
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

PURPOSE CAPTIVATE ( NCT02910583 ), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leuk

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c35a6a06435710a766e71312c7d53b84
https://doi.org/10.1200/jco.21.00807

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2.

Autor: Sehn, L. H, Chamuleau, M., Lenz, G., Clausen, M. R., Haioun, C., Izutsu, K., Davies, A., Zhu, J., Oki, T., Szafer‐Glusman, E., Conlon, R., Chiou, H., Ipe, D., Elliot, B., Wu, J., Salles, G.

Publikováno v: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p849-850, 2p

CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Autor: Tam, C. S. L, Allan, J. N, Siddiqi, T, Kipps, T. J, Jacobs, R, Opat, S, Barr, P. M, Tedeschi, A, Trentin, L, Bannerji, R, Jackson, S, Kuss, B, Moreno, C, Szafer‐Glusman, E, Russell, K, Zhou, C, Ninomoto, J, Dean, J. P, Ghia, P, Wierda, W. G

Publikováno v: Hematological Oncology; Jun2021 Supplement S2, Vol. 39, p1-3, 3p